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INTRODUCTION
Craniopharyngiomas are histologically benign tumors that
originate from epithelial rests or from areas of squamous meta-
plasia related to the hypophysis. Despite recent advances in
aggressive and conservative approaches to these tumors and
their benign histological nature, they are associated with a
significant morbidity. 
There are two major opposing views as to the surgical ap-
proach to these lesions (1). The ideal approach is a total exci-
sion, owing to the fact that a partial or subtotal excision will
bring sooner or later to a recurrence. However, because a total
excision is not always possible in every case and often results
in major deficits such as hypothalamic dysfunction and adja-
cent nerve injury, a palliative operation in combination with
radiotherapy or chemotherapy may be preferred. 
In 1985, Takahashi et al. demonstrated a reduction of the
cystic portion in four of seven children with cystic craniopha-
ryngioma after direct injection of bleomycin into the cyst (1).
Ever since, this result has been confirmed by several authors
(2-7). The rationales for application of intratumoral bleomycin
injection as an adjuvant therapy for craniopharyngioma are:
1) in most cases, the tumor is associated with a cyst; 2) it is
an epithelial tumor; 3) although the ideal treatment for cra-
niopharyngioma is a complete excision, total removal is not
possible in many cases, where the tumor locates adjacent to
the hypothalamus, pituitary gland, optic apparatus, or intra-
cranial artery causing adhesion; 4) although the remaining
tumor may be treated with external or interstitial irradiation,
this may cause serious side effects; and 5) intracystic appli-
cation of bleomycin may provide a long duration of effective
concentration.
Here, we report long-term results of intratumoral bleomy-
cin injection for craniopharyngioma in our cases, together
with a review of literature, focusing mainly on the feasibili-
ty and limitations of the modality. 
MATERIALS AND METHODS
Patients 
A total of 10 patients (5 males and 5 females; age range,
3-65 yr; mean age, 30.2 yr) who were treated for cystic cran-
iopharyngioma with partial or subtotal tumor removal and
postoperative intratumoral injections of bleomycin from 1992
to 1999 was included. The follow-up duration ranged from
12 to 79 months (mean, 33.9 months).
All patients were evaluated for endocrine dysfunction with
baseline hormonal profile. Headache and visual disturbance
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Outcome of Postoperative Intratumoral Bleomycin Injection for Cystic
Craniopharyngioma 
Total excision is a treatment of choice in preventing the relapse of craniopharyn-
gioma, but for tumors involving an extensive area, it is often associated with an
increased risk of complications. We have performed a partial or subtotal tumor
removal followed by repeated injection of bleomycin into the remaining tumor
through a subcutaneous reservoir as postoperative adjuvant therapy. A retro-
spective review of clinical, radiological, and surgical data was performed for 10
patients (5 males and 5 females; age, 3-65 yr; follow-up duration, 12-79 months)
with cystic craniopharyngiomas. The measurements of lactate dehydrogenase
(LDH) level at each aspiration were performed. The shrinkage and/or stabiliza-
tion of tumor was initially noted in all cases. The recurrence of tumor was seen
in 4 cases (40%). The decreased or increased level of LDH was interpreted as
tumor shrinkage or recurrence, respectively. The transient toxic reactions were
observed in 3 patients (30%). Our study demonstrates that postoperative bleo-
mycin injection for cystic craniopharyngioma, although does not appear to eradi-
cate the tumor, decreases and stabilizes the tumor size, when used as an adju-
vant therapy in young patients. 
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resulting from the mass effect were the most common clini-
cal findings, whereas personality change and disorientation
were observed less frequently. 
Methods 
The neuro-radiological assessment and endocrine study
were performed before and after surgical treatment. Because
the tumor, of a cystic or mixed type, adhered to the surround-
ing structures, only a partial or subtotal removal of tumor
was performed. For the cases with only cystic type, stereo-
tactic surgery was performed under general anesthesia. The
cyst was punctured and a catheter was inserted into the cyst
using the sliding stylets of the stereotactic system. A side-
inlet reservoir (Ommaya reservoir) was attached to the catheter,
and replaced under the skin. Cytological examination of the
cyst fluid revealed that these tumors were craniopharyn-
giomas. However, for the mixed type, solid portions were
surgically excised much as possible to prevent the recurrence
from these regions and to establish the histological diagno-
sis, while the remaining cystic portions were left intact. A
silastic catheter was then inserted into the center of cyst and
connected with Ommaya reservoir percutaneously. Bleomycin
was injected repeatedly through a subcutaneous Ommaya
reservoir firmly connected to a catheter placed in the cystic
portion after operations. The protocol of bleomycin injection
was mainly adopted from Takahashi et al. (1) with minor
modifications. Briefly, the administration of bleomycin start-
ed 10-15 days after operation. This time interval was report-
ed to be sufficient to establish the secured position without
any leakage (1). However, each case was confirmed of radio-
logic control (injection of contrast into the cyst) which de-
monstrated the absence of any leakage from cyst. The inter-
vals of each bleomycin injection were 2-7 days and the dosage
of bleomycin was 2-5 mg in average. Bleomycin was deliv-
ered after aspiration of 2-6 mL of cystic fluid. The injection
was performed slowly and discontinued if side effects (hyper-
somnia, mental change, and visual disturbance, etc) occurred.
The total dose was 15-180 mg. The measurements of lactate
dehydrogenase (LDH) at each aspiartion were compared. Shunt
placement was required in some patients for the treatment
of hydrocephalus at the time of initial resection or during
follow-up period. 
RESULTS
Table 1 summarizes the clinical results of the ten patients.
Initially, the remission (shrinkage or stabilization of tumor
size) was demonstrated in all patients by CT or MRI studies
compared with preoperation state (Fig. 1-4). Finally, for the
functional outcome, eight patients returned to a full social
life successfully after treatment for follow-up period. Recur-
rence was seen in four (40%) patients during follow-up, all
of these having mixed type. These patients underwent reop-
erations (partial or subtotal removal) and two of them received
adjunctive radiotherapy. The second intratumoral bleomycin
chemotherapy was done after reoperation in one patient. An-
other patient died after reoperation due to meningitis and
fulminant pneumonia. The mean time to progression (inter-
val from initial remission to recurrence) of these 4 patients
was 16.3 months. After 6 yr of follow-up, there was one pa-
tient kept in a bed-ridden state after the first cycle of chemo-
therapy. This was considered be a toxic reaction of bleomycin. 
Repeated intratumoral injection of bleomycin brought to
a gradual clearing in coloration of the cystic fluid and a de-
crease in LDH activity, especially the L4 and L5 fractions, ex-
cept of two cases. In these two cases, the LDH activity was
initially decreased and the L4 and L5 fractions were nearly flat
at first 2 months, however, the activity increased to 1,000-
2,000 units and the L4 and L5 fractions were also elevated
progressively. Despite these findings, there was no recurrence
in these cases based on radiologic studies. In recurred cases,
LDH activity was increased up to 3,000 units along with ele-
vations of L4 and L5 fractions, compared with the decreased
LDH activity and normal levels of L4 and L5 fractions before
1 4, F Gait disturbance, nystagmus good 30 - < 500 -/-
2  14, M Hemiparesis, short stature poor 79 ? < 2,000 -/-
3 11, F Drowsiness, hyperprolactinemia good 60 - < 500 -/+
4 17, M Personality change, incontinence, ataxia good 18 visual disturbance > 3,000 +/+ 6       
5 65, M Incontinence, disorientation dead 13 cerebellar infarction > 3,000 +/+ 12       
6 65, F General weakness, hemianopsia good 12 - < 1,000 -/-
7 35, F Headache, visual disturbance good 26 hypersomnia < 1,000 -/-
memory impairment
8 47, M Gait disturbance, papilledema good 40 - > 3,000 +/+ 25
9 41, F Headache, personality change good 28 transient mental change > 3,000 +/+ 22
10 3, M Hemiparesis good 33 - < 2,000 -/-
Patient Age (yr),
Sex
Clinical findings
LDH 
level
Recur/ 
Hydro
Final functional
outcome
Follow-up 
period (mos)
Toxic 
reaction
TTP 
(mos)
Table 1. Summary of clinical cases (n=10)
M: Male, F: Female, Good: normal independent functioning, Poor: bed ridden, Recur: recurrence, Hydro: hydrocephalus, DI: diabetes insipidus, ?:
not determined, but may be toxic reaction, TTP: time to progression.256 D.H. Park, J.Y. Park, J.H. Kim, et al.
recurrence. Therefore, the very high LDH activity with ele-
vation of L4 and L5 isozyme fractions can be considered as a
marker of recurrence. 
Complications from operation and chemotherapy were tran-
sient diabetes insipidus in 3 cases (30%), subdural fluid col-
lection in 2 (20%), meningitis in 1 (10%), wound infection
in 1 (10%), and toxic reactions such as hypersomnia, men-
tal and personality change, memory impairment and visual
disturbance in 3 (30%). One patient developed a cerebellar
infarction two months after the administration of bleomycin. 
DISCUSSION
Craniopharyngioma is a common benign intracranial tumor
occurring in childhood and young adults but may be observed
in any age group. Histologically, this tumor exhibits benign
stratified epithelium (8). Despite its benign nature, it often
causes neurological and endocrinological impairment, or even
death, because it may involve such vital structures as the hy-
pothalamus, optic nerves, and pituitary stalk. Hence, opti-
mal therapy for craniopharyngioma is still controversial. Many
Fig. 1. Preoperative brain MRI in a 3-yr-old boy who presented with right hemiparesis (Patient No. 10).
Fig. 2. Brain CT taken 20 months after a partial tumor removal and postoperative intracavitary bleomycin injection in Patient No. 10. Postoperative Intratumoral Bleomycin for Cystic Craniopharyngioma  257
neurosurgeons believe that total excision is the only reliable
approach to prevent recurrence (9-13). However, even after
total resection, the recurrence rate is high in the first 3 yr
after surgery and the severity of endocrinological disturbances
such as diabetes insipidus and related impairment in growth
and development tend to correlate with extensiveness of resec-
tion (1, 5). In the series of Yasargil et al., the overall mortal-
ity rate and recurrence rate were 17% and 7%, respectively,
even after aggressive radical excision of the tumors (14). Some
series indicated that the radical surgical intervention was asso-
ciated with a 40% incidence of hypothalamic damage and a
19% incidence of visual impairment (15, 16). These results
led other surgeons to favor a conservative surgical approach
combined with external radiotherapy, radiosurgery, colloidal
radioisotope intracavitary irradiation, and intracavitary bleo-
mycin injection (1-7, 17-19). Radiotherapy may be effective
in preventing the recurrence of tumor when total excision is
impossible, however, because craniopharyngioma is histolog-
ically a benign tumor occurring adjacent to the hypothala-
mus and pituitary gland, radiotherapy should be considered
Fig. 3. Preoperative brain MRI in a 65-yr-old female who presented with general weakness and hemianopsia (Patient No. 6).
Fig. 4. Brain CT of Patient No. 6 six months after a partial tumor removal and intracavitary bleomycin injection.258 D.H. Park, J.Y. Park, J.H. Kim, et al.
carefully, especially in childhood and young adults.
Because these tumors frequently present with cystic com-
ponents and only 10% of them are completely solid (7, 20),
they constitute a special clinical entity with respect to its treat-
ment. Other alternatives to radical surgery in cystic cranio-
pharyngioma have also been described, including drainage
techniques and intracavitary injection of radioactive colloidal
solutions or chemotherapeutic agents. The antineoplastic
properties of bleomycin, an antibiotic produced by Strepto-
myces verticillus, were first discovered by Umezawa and the
coworkers in 1966 (21). Its action is based mainly on the
inhibition of DNA synthesis and, to a lesser extent, RNA
synthesis. Bleomycin also inhibits the synthesis of proteins.
It was found to be effective on various types of epithelial
tumors and cellular cultures of craniopharyngioma. Several
studies demonstrated that intracystic application of bleomycin
decreased the secretion of cystic fluid and caused tumor cells
to degenerate (1-4). Although there were great variations
among the reported series with respect to treatment proto-
col, size of cyst, timing of injections, number of treatment
cycles, and dose of bleomycin, most reports favored the intra-
cavitary bleomycin injection (1-7). Takahashi et al. present-
ed their results of seven patients who had received multiple
bleomycin injections (1). Most of the patients with tumors
of a cystic type survived, and were able to live a full social
life. The recent report by Savas et al. showed that polycystic
craniopharyngioma was successfully treated with intracavi-
tary use of bleomycin (6). On the other hand, the patients
with tumors of a mixed or solid type experienced tumor re-
currence and had poor outcomes. The advantages of bleo-
mycin over the surgical resection of the cystic craniopharyn-
gioma is the simplicity and feasibility of repeating the cycles
of bleomycin without additional surgical approach and the
possibility of sparing residual endocrinologic functions of the
hypophysis (16). Moreover, even in case of recurrence after
administration of bleomycin, prior treatment with bleomycin
did not interfere or cause any additional difficulties during
second operation. The total LDH activity and pattern of its
fractions, namely, elevated L4 and L5 fractions, were closely
related to the tumor malignancy and recurrence (1). In our
series, 4 recurrent cases were of a mixed type and had a high
level of total LDH (>3,000 units) during follow-up. These
results indicate that the local injection of bleomycin is not
effective against craniopharyngioma of a mixed or solid type,
but is markedly effective against that of a cystic type. Thus,
the type of the tumor and LDH level may be considered im-
portant prognostic factors. 
Interstitial pneumonia, pulmonary fibrosis, fever, sclero-
derma-like changes in the skin, and alopecia have been re-
ported as adverse reactions to bleomycin administration (6).
Theoretically, bleomycin may also pose serious problems in-
volving direct actions of the drug on normal brain tissue if
the drug leaks out of the cyst, although only a few such cases
have been reported (1, 4, 22, 23). Haisa et al. reported a case
of cystic craniopharyngioma in which toxic effects of bleomy-
cin on the hypothalamus were observed after intracavitary
administration of bleomycin (22). We believe that the post-
treatment symptoms of three patients of our series, although
transient, such as hypersomnia, thermal dysfunction, memo-
ry impairment, and behavioral changes, were the toxic effects
of bleomycin on the hypothalamus. Broggi et al. reported a
patient who experienced a stroke in the middle cerebral artery
3 months after completion of the treatment (4). They pro-
posed that the ischemic lesion might have been mediated
by vasospasm secondary to bleomycin leakage in the middle
cerebral artery cistern. One patient in our series developed
ipsilateral superior cerebellar artery territory infarction 2
months after intracavitary bleomycin injection. It is unclear
whether this was directly due to the bleomycin. Despite its
potential toxicities, the majority of toxicity were transient
and not serious. 
The postoperative adjunctive intracavitary bleomycin injec-
tion may be recommended when total excision of cystic cran-
iopharyngioma seems dangerous or not possible, especially
in young patients. The advantage of its use in young chil-
dren with cystic craniopharyngioma is that it can control
the tumor permitting further growth of the patient until a
new treatment is available. Careful and meticulous applica-
tion and handling of the technique will not only aid in pro-
ducing better outcome but also will reduce its potential com-
plications.
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